Disease-associated hepatic mRNA

"Disease-associated hepatic mRNA" refers broadly to any liver mRNA transcript whose expression levels change in the context of liver disease. Differential mRNA expression in the liver underlies disease pathways and is a source of both disease biomarkers and putative drug targets, but the phrase does not specify any one gene, protein, or established therapeutic target. Large-scale RNA profiling helps identify which mRNAs are associated with specific hepatic disease states, such as NAFLD, fibrosis, inflammation, or hepatocellular carcinoma. Approaches targeting hepatic mRNAs for therapy—such as antisense oligonucleotides, siRNAs, and therapeutic mRNA constructs—focus on the functional protein products these mRNA species encode, not on the mRNA as a standalone drug target. Summary of why this entry is incorrect as a molecular target: "Disease-associated hepatic mRNA" is a collective, non-specific term, not the canonical name of a unique target or molecule. It refers to many possible mRNAs that might be upregulated or downregulated in liver disease. A valid target entry must specify a precise gene, RNA species, or protein (for example, "Apolipoprotein B-100", "Low-density lipoprotein receptor", "Transforming growth factor beta 1", etc.), not a descriptive group or biomarker class.